Circadian rhythms and cancer chemotherapy

Focan, C

doi:10.1016/0163-7258(95)00009-6

Cited by 45 publications

(44 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We confirm in this end-report preliminary data on the feasibility of a quadri-chronotherapy association with 5FU-FOL carbo and CPT11 for first-or second-line treatment of metastatic colorectal cancer [9].…”

Section: Discussion-commentssupporting

confidence: 75%

“…Recently we have reported an interesting therapeutic index for a chronotherapy association including 5FU, FOL and carboplatin (carbo) [8,[15][16][17]. This chronotherapy schedule delivered 4 days every 2 weeks (FFC4-10) initially tested in a phase II with half of the patients previously treated [15], was further assessed in a large phase II as first-line treatment [16].…”

Section: Introductionmentioning

confidence: 98%

“…The chronobiological-based administration [8][9][10] of 5FU-FOL and LOHP (FOLFOX) has been able not only to significantly reduce prominent toxicities (i.e., mucitis, diarrhoea, neurological) of the combination, but also to improve tumoral outcome, at least when the same chemotherapy program in terms of duration was applied [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phase I – II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study

Focan

Kreutz

Graas

et al. 2013

Pathologie Biologie

Self Cite

View full text Add to dashboard Cite

Section: Discussion-commentssupporting

confidence: 75%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase I – II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study

Focan

Kreutz

Graas

et al. 2013

Pathologie Biologie

Self Cite

View full text Add to dashboard Cite

“…Circadian and ultradian (high frequency) rhythms have been observed in experimental tumors. The DNA synthesis and/or mitotic rhythms have been reported in tumor models of mice, rats, and hamsters as summarized in Table 2 (8). We recently found a marked circadian variation in G 2 /M-phase cells in MA13/C mammary adenocarcinoma of C3H/HeN mice.…”

Section: Cell Proliferation Rhythms In Tumorsmentioning

confidence: 95%

Tumor-based rhythms of anticancer efficacy in experimental models

Granda

Lévi

2002

Chronobiology International

View full text Add to dashboard Cite

Experimental tumor models constitute a prerequisite toward chronotherapy testing in cancer patients. Studies in experimental models are required to understand the relation between tumor rhythms and antitumor treatments efficacy. In healthy tissues, cell proliferation, and differentiation processes are regulated precisely and exhibit marked circadian rhythmicity. Experimental and human tumors can retain circadian rhythms or display altered oscillations. Healthy tissues can also display rhythm modifications, possibly related to cancer stage. Cellular rhythms modulate the metabolism of cytotoxic agents and the cellular response to them; hence, they determine the chronopharmacology of anticancer drugs. Circadian rhythms in host tolerability and/or cancer chemotherapy efficacy have been demonstrated with nontoxic doses of drugs in several experimental tumor models, while in other ones a circadian-time effect was only seen within a specific dose range. The usual coupling between tolerability and efficacy rhythms of anticancer agents has resulted in significant improvement of their therapeutic index. Results of laboratory animal studies have been extrapolated to the design of clinical cancer therapy trials involving a chronobiological approach.

show abstract

“…Derzeit werden zahlreiche multizentrische europäische Studien unter Leitung der EORCT (European Organisation of Rhythm Controlled Therapy) durchgeführt, mit denen eine Chronotherapie mit Zytostatika bei den verschiedensten Tumorerkrankungen mit einer konventionellen Therapie verglichen werden, um an großen Kollektiven den Stellenwert einer chronomodulierten Therapie onkologischer Erkrankungen zu validieren (Übersicht s. [6,23]). …”

Section: Chronopharmakologie Der Koronaren Herzkrankheitunclassified

Zirkadiane Rhythmen und klinische Pharmakologie

Lemmer

2004

Internist

View full text Add to dashboard Cite

Almost all physiological functions in animal and man including vital signs display significant daily variations. The existence of internal clock(s) triggering circadian rhythms is now well established. In man, also the onset of certain diseases such as asthma attacks, coronary infarction, angina pectoris and peptic ulcers is not randomly distributed over 24 hours of a day. These rhythmic changes may have implications for drug therapy: In man more than 60 different drugs were shown to exhibit pronounced daily variations in their pharmacokinetics and/or in their effects or side effects. This data demonstrate that the time of day has to be taken into account as an additional parameter influencing the pharmacokinetics, the efficacy and the therapeutic range of drug therapy.

show abstract

Circadian rhythms and cancer chemotherapy

Cited by 45 publications

References 104 publications

Phase I – II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study

Phase I – II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study

Tumor-based rhythms of anticancer efficacy in experimental models

Zirkadiane Rhythmen und klinische Pharmakologie

Contact Info

Product

Resources

About